Anna Punga

ACADEMIC EDUCATION/ UNIVERSITY Medical School with the emphasis on research; Uppsala University 1997-2003. Graduated in January 2003. Degree of Doctor of Philosophy (Faculty of Medicine) February 2nd, 2007, Department of Neuroscience, Uppsala University. Thesis title: “MuSK antibody(+) versus AChR antibody(+) myasthenia gravis: clinical, neurophysiological and morphological aspects.” PROFESSIONAL EXPERIENCE  Postdoctoral fellow, Group of Prof Markus A Rüegg, Department of Neurobiology/Pharmacology, Biozentrum, University of Basel, Switzerland. April 2009-present.  Postdoctoral scientist, Department of clinical neurophysiology, Uppsala University Hospital. February 2007- May 2008.  Resident physician, Departments of neurology and clinical neurophysiology, Uppsala University Hospital, Sweden. May 2005-May 2008.  Medical Internship at Gävle Hospital, Gävle, Sweden. February 2003-April 2005. Obtained medical licence in April 2005.  PhD student, Institution of Neuroscience, Uppsala University, Sweden. August 2003-February 2007. Supervisor: Prof Erik Stålberg. PEER REVIEWER Neurology India (since 2006) Medical science monitor (since 2006) European Journal of Neurology (since 2007) Neurological sciences (since 2009) Diabetologia (since 2009) PROFESSIONAL ORGANISATIONS (MEMBER) EuroMyasthenia network AANEM (American Association of neuromuscular & electrodiagnostic medicine) Swedish medical association Swedish association for clinical neurophysiology (faculty 2005-2007) CURRENT FUNDING April 2009- March 2011: Swedish Association for Medical Research (SSMF) Postdoctoral grant. 2004-2010: Palle Ferbs memorial foundation for Myasthenia Gravis research. LIST OF PUBLICATIONS 1. Rostedt A, Sanders L, Edwards LJ, Massey JM, Sanders DB, Stålberg E: Predictive value of Single-Fibre Electromyography in a limb muscle in patients with Ocular Myasthenia Gravis. A retrospective study. J Clinical Neuromuscular Disease 2000; 2:6-9. 2. Rostedt A, Stålberg E: Joint pain and hyperalgesia due to pyridostigmine bromide in a patient with myasthenia gravis. Neurology 2004; 62: 835-836. 3. Rostedt A, Padua L, Stålberg E: Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in Myasthenia Gravis patients. Clinical Neurophysiology 2005; 9:2058-2064 4. Rostedt A, Padua L, Stålberg E: Correlation between regional myasthenic weakness and mental aspects of quality of life. Eur J Neurol 2006; 2:191-193 5. Rostedt A, Padua L, Stålberg E: Validation of the Swedish version of the disease specific Myasthenia Gravis questionnaire (MGQ). Neurol Sci. 2006; 27:91-96 6. Rostedt Punga A, Ahlqvist K, Bartoccioni E, Scuderi F, Marino M, Suomalainen A, Kalimo H, Stålberg E V. Neurophysiological and mitochondrial abnormalities in MuSK antibody seropositive Myasthenia Gravis compared to other immunological subtypes. Clinical Neurophysiology 2006;117:1434-1443 7. Punga AR, Flink R, Askmark H, Stålberg E: Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve. 2006; 34(1):111-115. 8. Punga AR, Sawada M, Stålberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37(3):300-307. 9. Schreurs A, Stålberg E, Punga AR. Indication of peripheral nerve hyperexcitability in adult-onset subacute sclerosing panencephalitis (SSPE). Neurol Sci. 2008; 29(2):121-124. 10. Punga AR, Nygren I, Askmark H, Stålberg EV. Monozygous twins with neuromuscular transmission defects at opposite sides of the motor endplate. Acta Neurol Scand. 2009; 119(3): 207-211. 11. Punga AR, Stålberg EV. Acetylcholinesterase inhibitors in MG: To be or not to be? (Review) Muscle Nerve 2009: 39 (6):724-728.